Madison Vaccines Inc.
Vaccines for prostate cancer
This article was originally published in Start Up
Madison Vaccines Inc. is developing two candidates for prostate cancer: MVI-816 trains the patient’s immune system to recognize and attack the cancer as a foreign body by targeting a molecule called prostatic acid phosphatase (PAP), which is uniquely displayed on the surface of prostate cancer cells. Madison Vaccines’ second product, MVI-118, targets cells that over-express the androgen receptor.
You may also be interested in...
Gene editing has made a great many headlines of late, and one could be forgiven for thinking the field was saturated, but Homology Medicines Inc. offers something new. Its platform relies on a different mechanism, known as homologous recombination, and the start-up's management team believes the approach can get around some of the potential limitations found in other gene-editing technologies.
X4 Pharmaceuticals Inc. spun out from Sanofi to develop compounds that target the CXCR4/CXCL12 receptor pathway to restore immune cell surveillance against cancer.
Over the past five years, pharma companies have cast an increasingly wide research net in search of cancer immunotherapy drug combinations that can help patients who have failed monotherapies.